Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors

Soluble guanylate cyclase (sGC) encompasses α and β subunits. This study examined the expression of α1, α2, β1, and β2 subunits in the malignant and benign breast tumors using the Western blot  analysis. Both benign and malignant tumors showed a significantly higher expression of the α1 subunit in c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2020-02, Vol.235 (2), p.1358-1365
Main Authors: Mohammadoo‐Khorasani, Milad, Karami Tehrani, Fatemeh, Atri, Morteza
Format: Article
Language:English
Subjects:
Anticancer properties
Antitumor activity
Benign
Breast cancer
ErbB-2 protein
Guanylate cyclase
Isoenzymes
sGC subunits
soluble guanylyl cyclase expression
Tumors
α1, α2
β1, β2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773
cites cdi_FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773
container_end_page 1365
container_issue 2
container_start_page 1358
container_title Journal of cellular physiology
container_volume 235
creator Mohammadoo‐Khorasani, Milad
Karami Tehrani, Fatemeh
Atri, Morteza
description Soluble guanylate cyclase (sGC) encompasses α and β subunits. This study examined the expression of α1, α2, β1, and β2 subunits in the malignant and benign breast tumors using the Western blot  analysis. Both benign and malignant tumors showed a significantly higher expression of the α1 subunit in comparison with normal tissues (p 
doi_str_mv 10.1002/jcp.29054
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2252266564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2317564858</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773</originalsourceid><addsrcrecordid>eNp1kcFqFTEUhoMo9ra68AUk4MaC0yZnksmMO7morRQUrOuQyZxb55JJrskEHXc-kj5In8m0t7oQ3Jzzw_-dnwM_IU84O-GMwenW7k6gY1LcIyvOOlWJRsJ9sioerzop-AE5TGnLGOu6un5IDmoOirVMrMiPj8Hl3iG9ysYvzsxI7WKdSUjHFNB_XyZML-nlZ6T4bRcxpTF4Gjb0-id_UQaU8aso44cigKbcZz_OiY6ezuWoRz9e-Vt7Mq5I42faRzRppnOeQkyPyIONcQkf3-0j8unN68v1WXXx_u35-tVFZaFpRQUoBrANdgZU3dbKmME2A2MowYgagW-gKR5DHFAZa1G1nWRCKuhN2yhVH5Hn-9xdDF8ypllPY7LonPEYctIAEqBpZCMK-uwfdBty9OU7DTVXBWllW6jjPWVjSCniRu_iOJm4aM70TS-69KJveyns07vE3E84_CX_FFGA0z3wdXS4_D9Jv1t_2Ef-BsQDmTk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2317564858</pqid></control><display><type>article</type><title>Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors</title><source>Wiley</source><creator>Mohammadoo‐Khorasani, Milad ; Karami Tehrani, Fatemeh ; Atri, Morteza</creator><creatorcontrib>Mohammadoo‐Khorasani, Milad ; Karami Tehrani, Fatemeh ; Atri, Morteza</creatorcontrib><description><![CDATA[Soluble guanylate cyclase (sGC) encompasses α and β subunits. This study examined the expression of α1, α2, β1, and β2 subunits in the malignant and benign breast tumors using the Western blot  analysis. Both benign and malignant tumors showed a significantly higher expression of the α1 subunit in comparison with normal tissues (p < 0.0001). In contrast, the expression of α2 and β2 sGC were significantly lower in these tumors than normal tissues (p < .0015 and p < .001, p < .007 and p < .0001, respectively). The expression level of α1 sGC was significantly correlated with ER + PR+ (p < .0001). A significant correlation was also detected for sGC‐α1 and ‐α2 expression with c‐erbB2‐negative status (p < .01). However, the expression level of sGC was not associated with tumor stage, tumor grade, or other clinicopathological features. In conclusion, as the expression of α1 sGC is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity. The expression of α1 soluble guanylate cyclase (sGC) is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity.]]></description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.29054</identifier><identifier>PMID: 31270804</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Anticancer properties ; Antitumor activity ; Benign ; Breast cancer ; ErbB-2 protein ; Guanylate cyclase ; Isoenzymes ; sGC subunits ; soluble guanylyl cyclase expression ; Tumors ; α1, α2 ; β1, β2</subject><ispartof>Journal of cellular physiology, 2020-02, Vol.235 (2), p.1358-1365</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773</citedby><cites>FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773</cites><orcidid>0000-0002-9768-946X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31270804$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohammadoo‐Khorasani, Milad</creatorcontrib><creatorcontrib>Karami Tehrani, Fatemeh</creatorcontrib><creatorcontrib>Atri, Morteza</creatorcontrib><title>Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description><![CDATA[Soluble guanylate cyclase (sGC) encompasses α and β subunits. This study examined the expression of α1, α2, β1, and β2 subunits in the malignant and benign breast tumors using the Western blot  analysis. Both benign and malignant tumors showed a significantly higher expression of the α1 subunit in comparison with normal tissues (p < 0.0001). In contrast, the expression of α2 and β2 sGC were significantly lower in these tumors than normal tissues (p < .0015 and p < .001, p < .007 and p < .0001, respectively). The expression level of α1 sGC was significantly correlated with ER + PR+ (p < .0001). A significant correlation was also detected for sGC‐α1 and ‐α2 expression with c‐erbB2‐negative status (p < .01). However, the expression level of sGC was not associated with tumor stage, tumor grade, or other clinicopathological features. In conclusion, as the expression of α1 sGC is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity. The expression of α1 soluble guanylate cyclase (sGC) is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity.]]></description><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Benign</subject><subject>Breast cancer</subject><subject>ErbB-2 protein</subject><subject>Guanylate cyclase</subject><subject>Isoenzymes</subject><subject>sGC subunits</subject><subject>soluble guanylyl cyclase expression</subject><subject>Tumors</subject><subject>α1, α2</subject><subject>β1, β2</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kcFqFTEUhoMo9ra68AUk4MaC0yZnksmMO7morRQUrOuQyZxb55JJrskEHXc-kj5In8m0t7oQ3Jzzw_-dnwM_IU84O-GMwenW7k6gY1LcIyvOOlWJRsJ9sioerzop-AE5TGnLGOu6un5IDmoOirVMrMiPj8Hl3iG9ysYvzsxI7WKdSUjHFNB_XyZML-nlZ6T4bRcxpTF4Gjb0-id_UQaU8aso44cigKbcZz_OiY6ezuWoRz9e-Vt7Mq5I42faRzRppnOeQkyPyIONcQkf3-0j8unN68v1WXXx_u35-tVFZaFpRQUoBrANdgZU3dbKmME2A2MowYgagW-gKR5DHFAZa1G1nWRCKuhN2yhVH5Hn-9xdDF8ypllPY7LonPEYctIAEqBpZCMK-uwfdBty9OU7DTVXBWllW6jjPWVjSCniRu_iOJm4aM70TS-69KJveyns07vE3E84_CX_FFGA0z3wdXS4_D9Jv1t_2Ef-BsQDmTk</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Mohammadoo‐Khorasani, Milad</creator><creator>Karami Tehrani, Fatemeh</creator><creator>Atri, Morteza</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9768-946X</orcidid></search><sort><creationdate>202002</creationdate><title>Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors</title><author>Mohammadoo‐Khorasani, Milad ; Karami Tehrani, Fatemeh ; Atri, Morteza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Benign</topic><topic>Breast cancer</topic><topic>ErbB-2 protein</topic><topic>Guanylate cyclase</topic><topic>Isoenzymes</topic><topic>sGC subunits</topic><topic>soluble guanylyl cyclase expression</topic><topic>Tumors</topic><topic>α1, α2</topic><topic>β1, β2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohammadoo‐Khorasani, Milad</creatorcontrib><creatorcontrib>Karami Tehrani, Fatemeh</creatorcontrib><creatorcontrib>Atri, Morteza</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohammadoo‐Khorasani, Milad</au><au>Karami Tehrani, Fatemeh</au><au>Atri, Morteza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2020-02</date><risdate>2020</risdate><volume>235</volume><issue>2</issue><spage>1358</spage><epage>1365</epage><pages>1358-1365</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract><![CDATA[Soluble guanylate cyclase (sGC) encompasses α and β subunits. This study examined the expression of α1, α2, β1, and β2 subunits in the malignant and benign breast tumors using the Western blot  analysis. Both benign and malignant tumors showed a significantly higher expression of the α1 subunit in comparison with normal tissues (p < 0.0001). In contrast, the expression of α2 and β2 sGC were significantly lower in these tumors than normal tissues (p < .0015 and p < .001, p < .007 and p < .0001, respectively). The expression level of α1 sGC was significantly correlated with ER + PR+ (p < .0001). A significant correlation was also detected for sGC‐α1 and ‐α2 expression with c‐erbB2‐negative status (p < .01). However, the expression level of sGC was not associated with tumor stage, tumor grade, or other clinicopathological features. In conclusion, as the expression of α1 sGC is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity. The expression of α1 soluble guanylate cyclase (sGC) is upregulated and α2 and β2 sGC are downregulated in malignant breast tumors. Variations in the expression of sGC isoenzymes may be suggested as an indicator to confirm the enzyme antitumor activity.]]></abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31270804</pmid><doi>10.1002/jcp.29054</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9768-946X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0021-9541
ispartof Journal of cellular physiology, 2020-02, Vol.235 (2), p.1358-1365
issn 0021-9541
1097-4652
language eng
recordid cdi_proquest_miscellaneous_2252266564
source Wiley
subjects Anticancer properties
Antitumor activity
Benign
Breast cancer
ErbB-2 protein
Guanylate cyclase
Isoenzymes
sGC subunits
soluble guanylyl cyclase expression
Tumors
α1, α2
β1, β2
title Soluble guanylate cyclase isoenzymes: The expression of α1, α2, β1, and β2 subunits in the benign and malignant breast tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T11%3A49%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20guanylate%20cyclase%20isoenzymes:%20The%20expression%20of%20%CE%B11,%20%CE%B12,%20%CE%B21,%20and%20%CE%B22%20subunits%20in%20the%20benign%20and%20malignant%20breast%20tumors&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Mohammadoo%E2%80%90Khorasani,%20Milad&rft.date=2020-02&rft.volume=235&rft.issue=2&rft.spage=1358&rft.epage=1365&rft.pages=1358-1365&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.29054&rft_dat=%3Cproquest_cross%3E2317564858%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2684-2e4d2c6e9a273837aadc6d00e52a43e21f269a20eede7acce789504572ba86773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2317564858&rft_id=info:pmid/31270804&rfr_iscdi=true